blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2882446

EP2882446 - PROPHYLACTIC AND NUTRACEUTICAL THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.03.2019
Database last updated on 31.08.2024
FormerThe patent has been granted
Status updated on  06.04.2018
FormerGrant of patent is intended
Status updated on  23.03.2018
FormerExamination is in progress
Status updated on  31.01.2018
FormerGrant of patent is intended
Status updated on  22.10.2017
FormerExamination is in progress
Status updated on  27.01.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
HAMLET Pharma AB
BMC D10
Klinikgatan 32
222 42 Lund / SE
[2018/10]
Former [2015/25]For all designated states
HAMLET Pharma AB
Lilla Fiskaregatan 10
222 22 Lund / SE
Inventor(s)01 / SVANBORG, Catharina
Slottsgatan 32
S-21133 Malmo / SE
02 / PUTHIA, Manoj
Department of Microbiology
Immunology and Glycobiology (MIG)
Lund University
Solvegatan 23
S-223 62 Lund / SE
03 / HO, Chin Shing
Department of Microbiology
Immunology and Glycobiology (MIG)
Lund University
Solvegatan 23
S-223 62 Lund / SE
 [2015/25]
Representative(s)Greaves Brewster LLP
Copa House
Station Road
Cheddar, Somerset BS27 3AH / GB
[N/P]
Former [2015/25]Greaves, Carol Pauline
C P Greaves & Co
80 Church Road
Winscombe
North Somerset BS25 1BP / GB
Application number, filing date13762204.908.08.2013
[2018/19]
WO2013GB52132
Priority number, dateGB2012001423409.08.2012         Original published format: GB 201214234
GB2012001423709.08.2012         Original published format: GB 201214237
[2015/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014023976
Date:13.02.2014
Language:EN
[2014/07]
Type: A1 Application with search report 
No.:EP2882446
Date:17.06.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 13.02.2014 takes the place of the publication of the European patent application.
[2015/25]
Type: B1 Patent specification 
No.:EP2882446
Date:09.05.2018
Language:EN
[2018/19]
Search report(s)International search report - published on:EP13.02.2014
ClassificationIPC:A61K31/201, A61K38/38, A61K35/20, A61K47/12, A23L33/18
[2017/44]
CPC:
A61K38/38 (EP,US); A23L33/18 (EP,US); A61K31/201 (EP,US);
A61K35/20 (EP,US); A61K47/12 (EP,US); A61K9/0095 (EP,US);
A61P35/00 (EP,US) (-)
C-Set:
A61K31/201, A61K2300/00 (EP,US);
A61K35/20, A61K2300/00 (US,EP);
A61K38/38, A61K2300/00 (US,EP)
Former IPC [2015/25]A61K38/01, A61K38/16, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/25]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:PROPHYLAKTISCHE UND NUTRAZEUTISCHE THERAPIE[2015/25]
English:PROPHYLACTIC AND NUTRACEUTICAL THERAPY[2015/25]
French:THÉRAPIE PROPHYLACTIQUE ET NUTRACEUTIQUE[2015/25]
Entry into regional phase06.02.2015National basic fee paid 
06.02.2015Designation fee(s) paid 
06.02.2015Examination fee paid 
Examination procedure06.02.2015Amendment by applicant (claims and/or description)
06.02.2015Examination requested  [2015/25]
26.09.2016Despatch of a communication from the examining division (Time limit: M04)
26.01.2017Reply to a communication from the examining division
22.05.2017Despatch of a communication from the examining division (Time limit: M02)
23.06.2017Reply to a communication from the examining division
23.10.2017Communication of intention to grant the patent
29.01.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
29.01.2018Fee for grant paid
29.01.2018Fee for publishing/printing paid
26.03.2018Communication of intention to grant the patent
04.04.2018Receipt of the translation of the claim(s)
Divisional application(s)EP17187031.4  / EP3295953
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.09.2016
Opposition(s)12.02.2019No opposition filed within time limit [2019/16]
Fees paidRenewal fee
20.08.2015Renewal fee patent year 03
22.08.2016Renewal fee patent year 04
22.08.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL09.05.2018
AT09.05.2018
CY09.05.2018
CZ09.05.2018
EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
MK09.05.2018
PT09.05.2018
RO09.05.2018
RS09.05.2018
SI09.05.2018
SK09.05.2018
SM09.05.2018
TR09.05.2018
LU08.08.2018
MT08.08.2018
BG09.08.2018
GR10.08.2018
BE31.08.2018
IS09.09.2018
[2020/32]
Former [2020/31]AL09.05.2018
AT09.05.2018
CY09.05.2018
CZ09.05.2018
EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
MK09.05.2018
PT09.05.2018
RO09.05.2018
RS09.05.2018
SI09.05.2018
SK09.05.2018
SM09.05.2018
TR09.05.2018
LU08.08.2018
MT08.08.2018
BG09.08.2018
GR10.08.2018
BE31.08.2018
Former [2020/28]AL09.05.2018
AT09.05.2018
CZ09.05.2018
EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
PT09.05.2018
RO09.05.2018
RS09.05.2018
SI09.05.2018
SK09.05.2018
SM09.05.2018
TR09.05.2018
LU08.08.2018
MT08.08.2018
BG09.08.2018
GR10.08.2018
BE31.08.2018
Former [2020/16]AL09.05.2018
AT09.05.2018
CZ09.05.2018
EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
RO09.05.2018
RS09.05.2018
SI09.05.2018
SK09.05.2018
SM09.05.2018
TR09.05.2018
LU08.08.2018
MT08.08.2018
BG09.08.2018
GR10.08.2018
BE31.08.2018
Former [2020/08]AL09.05.2018
AT09.05.2018
CZ09.05.2018
EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
RO09.05.2018
RS09.05.2018
SI09.05.2018
SK09.05.2018
SM09.05.2018
LU08.08.2018
MT08.08.2018
BG09.08.2018
GR10.08.2018
BE31.08.2018
Former [2019/51]AL09.05.2018
AT09.05.2018
CZ09.05.2018
EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
RO09.05.2018
RS09.05.2018
SI09.05.2018
SK09.05.2018
SM09.05.2018
LU08.08.2018
BG09.08.2018
GR10.08.2018
BE31.08.2018
Former [2019/38]AT09.05.2018
CZ09.05.2018
EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
RO09.05.2018
RS09.05.2018
SI09.05.2018
SK09.05.2018
SM09.05.2018
LU08.08.2018
BG09.08.2018
GR10.08.2018
BE31.08.2018
Former [2019/26]AT09.05.2018
CZ09.05.2018
EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
RO09.05.2018
RS09.05.2018
SI09.05.2018
SK09.05.2018
SM09.05.2018
LU08.08.2018
BG09.08.2018
GR10.08.2018
Former [2019/21]AT09.05.2018
CZ09.05.2018
EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
RO09.05.2018
RS09.05.2018
SK09.05.2018
SM09.05.2018
LU08.08.2018
BG09.08.2018
GR10.08.2018
Former [2019/15]AT09.05.2018
CZ09.05.2018
EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
RO09.05.2018
RS09.05.2018
SK09.05.2018
SM09.05.2018
BG09.08.2018
GR10.08.2018
Former [2019/11]AT09.05.2018
CZ09.05.2018
EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
RO09.05.2018
RS09.05.2018
SK09.05.2018
SM09.05.2018
BG09.08.2018
GR10.08.2018
Former [2019/10]AT09.05.2018
CZ09.05.2018
EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
RO09.05.2018
RS09.05.2018
SK09.05.2018
BG09.08.2018
GR10.08.2018
Former [2019/09]EE09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
RS09.05.2018
BG09.08.2018
GR10.08.2018
Former [2018/52]HR09.05.2018
LT09.05.2018
LV09.05.2018
RS09.05.2018
BG09.08.2018
GR10.08.2018
Former [2018/51]HR09.05.2018
LT09.05.2018
LV09.05.2018
RS09.05.2018
BG09.08.2018
Former [2018/50]HR09.05.2018
LT09.05.2018
BG09.08.2018
Former [2018/47]LT09.05.2018
Cited inInternational search[X]WO9926979  (SVANBORG CATHARINA [SE], et al) [X] 1-35 * the whole document *;
 [X]WO03074547  (SVANBORG CATHARINA [SE], et al) [X] 1-4,8,10-14 * the whole document *;
 [X]WO2005082406  (HAMLET PHARMA AB [SE], et al) [X] 1-4,8,10-14 * the whole document *;
 [X]WO2008138348  (NYA HAMLET PHARMA AB [DK], et al) [X] 1-35 * the whole document *;
 [X]WO2010131237  (AGRICULTURE AND FOOD DEV AUTHO [IE], et al) [X] 1-35 * the whole document *;
 [X]  - SVANBORG C ET AL, "HAMLET kills tumor cells by an apoptosis-like mechanism--cellular, molecular, and therapeutic aspects", ADVANCES IN CANCER RESEARCH, ACADEMIC PRESS, US, (20030101), vol. 88, doi:10.1016/S0065-230X(03)88302-1, ISSN 0065-230X, pages 1 - 29, XP002254552 [X] 1-35 * pages 8,18 *

DOI:   http://dx.doi.org/10.1016/S0065-230X(03)88302-1
 [X]  - ANN-KRISTIN MOSSBERG ET AL, "Structure and function of human [alpha]-lactalbumin made lethal to tumor cells (HAMLET)-type complexes", FEBS JOURNAL, (20101101), vol. 277, no. 22, doi:10.1111/j.1742-4658.2010.07890.x, ISSN 1742-464X, pages 4614 - 4625, XP055015362 [X] 1-35 * page 4618 - page 4620 *

DOI:   http://dx.doi.org/10.1111/j.1742-4658.2010.07890.x
 [X]  - RAMMER PAUL ET AL, "BAMLET Activates a Lysosomal Cell Death Program in Cancer Cells", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, (20100101), vol. 9, no. 1, doi:10.1158/1535-7163.MCT-09-0559, ISSN 1535-7163, pages 24 - 32, XP009174347 [X] 1-35 * the whole document *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-09-0559
 [XY]  - SVENSSON M ET AL, "Conversion of alpha-lactalbumin to a protein inducing apoptosis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES - PNAS, NATIONAL ACADEMY OF SCIENCES, US, (20000411), vol. 97, no. 8, doi:10.1073/PNAS.97.8.4221, ISSN 0027-8424, pages 4221 - 4226, XP002530615 [X] 1-3,8,10-13 * page 4226 * [Y] 27-33

DOI:   http://dx.doi.org/10.1073/pnas.97.8.4221
 [XY]  - KNYAZEVA E L ET AL, "Who is Mr. HAMLET? Interaction of human [alpha]-lactalbumin with monomeric oleic acid", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (20081209), vol. 47, no. 49, ISSN 0006-2960, pages 13127 - 13137, XP009174339 [X] 1-3,8,10-13 * page 13129, column l * * page 13135, column r, paragraph l - page 13136, column l, paragraph 1 * [Y] 27-33

DOI:   http://dx.doi.org/10.1021/bi801423s
Examination   - MOSSBERG A K ET AL, "HAMLET Treatment Delays Bladder Cancer Development", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 183, no. 4, ISSN 0022-5347, (20100401), pages 1590 - 1597, (20100315), XP026967349
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.